Capitalizator.

Capitalize Yourself: Right Data. Real Growth.

Company Analysis

NTN Insider Trading

Ernexa Therapeutics Inc. | Pharmaceutical Preparations

Comprehensive Trading Performance Summary

The investment history of corporate insiders at Ernexa Therapeutics Inc. provides a unique lens into the internal conviction of the company's leadership. By analyzing SEC Form 4 filings, investors can track how directors and officers are allocating their own capital. High-conviction buying often signals that management believes the current market price significantly undervalues future growth prospects, while strategic selling might occur for personal liquidity or portfolio diversification. Monitoring these shifts in ownership is essential for understanding the alignment between management and shareholders in the Pharmaceutical Preparations sector.

Transactions on Chart

Open Full Chart
Filing Date Trade Date Reporting Person Relationship Type Price Qty Total, $ Owned After Change, %
2009-07-02 19:18 2009-07-01 Fidelity National Financial, Inc. 10% owner SELL $0.47 10,000 $4,726 6,619,611 -0.2%
2009-07-01 21:11 2009-06-30 Fidelity National Financial, Inc. 10% owner SELL $0.46 15,000 $6,876 6,629,611 -0.2%
2009-06-23 03:53 2009-06-18 Glassman Nicholas A Officer - EVP of Product and Technology BUY $0.47 10,000 $4,700 10,000 +100.0%
2009-06-23 04:07 2008-12-12 Berg Jeffrey Alan Director BUY $0.13 1,250,000 $162,500 5,445,600 +29.8%
2009-06-23 04:05 2008-09-18 Berg Jeffrey Alan Director BUY $0.25 1,544,145 $384,647 4,195,600 +58.2%
2009-06-23 03:58 2008-08-28 Berg Jeffrey Alan Director BUY $0.29 5,455 $1,558 2,651,455 +0.2%
2009-06-16 03:08 2009-06-15 Farricielli Joseph J. Jr. Director BUY $0.42 10,000 $4,200 110,000 +10.0%
2009-06-12 00:14 2009-06-09 Keymer Kenneth L Director BUY $0.40 9,900 $3,960 49,900 +24.8%
2009-06-11 01:46 2009-06-08 Keymer Kenneth L Director BUY $0.40 98,100 $39,240 98,100 +100.0%
2009-06-05 01:02 2009-06-04 Farricielli Joseph J. Jr. Director BUY $0.41 1,300 $533 100,000 +1.3%
2009-06-03 02:59 2009-06-01 Farricielli Joseph J. Jr. Director BUY $0.36 2,700 $972 98,700 +2.8%
2009-05-27 20:29 2009-05-22 Lewis Mary Beth Director BUY $0.40 10,000 $4,000 10,000 +100.0%
2009-05-21 20:25 2009-05-19 Farricielli Joseph J. Jr. Director BUY $0.39 20,000 $7,800 96,000 +26.3%
2009-05-20 02:54 2009-05-15 Trinad Capital Master Fund Ltd. 10% owner BUY $0.39 50,000 $19,405 8,900,093 +0.6%
2009-05-01 02:47 2009-04-28 Trinad Capital Master Fund Ltd. 10% owner BUY $0.35 75,000 $26,610 8,850,093 +0.9%
2009-04-15 02:00 2009-04-10 Trinad Capital Master Fund Ltd. 10% owner BUY $0.24 25,000 $5,948 8,775,093 +0.3%
2009-04-09 02:28 2009-04-06 Trinad Capital Master Fund Ltd. 10% owner BUY $0.27 25,000 $6,783 8,750,093 +0.3%
2009-03-24 02:42 2009-03-16 Trinad Capital Master Fund Ltd. 10% owner BUY $0.22 106,700 $23,335 8,725,093 +1.2%
2009-03-14 02:28 2009-03-11 Trinad Capital Master Fund Ltd. 10% owner BUY $0.22 100,160 $22,266 8,618,393 +1.2%
2009-02-14 05:57 2009-01-22 Trinad Capital Master Fund Ltd. 10% owner BUY $0.22 27,700 $6,158 8,518,233 +0.3%
2009-01-10 03:57 2009-01-07 Trinad Capital Master Fund Ltd. 10% owner BUY $0.15 75,341 $10,985 8,490,533 +0.9%
2009-01-08 03:50 2008-12-29 Trinad Capital Master Fund Ltd. 10% owner BUY $0.13 644,500 $83,398 8,380,192 +8.3%
2009-01-07 04:33 2009-01-02 Trinad Capital Master Fund Ltd. 10% owner BUY $0.14 35,000 $4,883 8,415,192 +0.4%
2009-01-01 01:38 2008-12-29 Trinad Capital Master Fund Ltd. 10% owner BUY $0.13 525,800 $66,829 8,261,492 +6.8%
2008-12-24 23:50 2008-12-23 Trinad Capital Master Fund Ltd. 10% owner BUY $0.13 45,965 $6,146 7,735,692 +0.6%
2008-12-23 22:30 2008-12-19 ARLEN GARY H Director BUY $0.12 10,000 $1,200 10,450 +2,222.2%
2008-12-20 04:03 2008-12-17 Trinad Capital Master Fund Ltd. 10% owner BUY $0.12 351,000 $42,120 7,689,727 +4.8%
2008-12-18 03:36 2008-12-16 Farricielli Joseph J. Jr. Director BUY $0.11 10,000 $1,100 76,000 +15.2%
2008-12-17 05:14 2008-12-12 Berg Jeffrey Alan Director BUY $0.13 1,250,000 $162,500 5,469,600 +29.6%
2008-12-12 05:23 2008-12-09 Trinad Capital Master Fund Ltd. 10% owner BUY $0.12 275,800 $32,600 7,338,727 +3.9%
2008-12-05 04:33 2008-12-03 Farricielli Joseph J. Jr. Director BUY $0.12 20,000 $2,400 66,000 +43.5%
2008-12-03 05:15 2008-11-28 Farricielli Joseph J. Jr. Director BUY $0.14 10,000 $1,400 46,000 +27.8%
2008-11-13 02:06 2008-11-11 Farricielli Joseph J. Jr. Director BUY $0.14 20,000 $2,750 36,000 +125.0%
2008-11-01 02:53 2008-10-29 Trinad Capital Master Fund Ltd. 10% owner BUY $0.13 300,600 $38,777 7,062,927 +4.4%
2008-10-03 02:12 2008-09-30 Trinad Capital Master Fund Ltd. 10% owner BUY $0.22 21,200 $4,664 6,762,327 +0.3%
2008-09-25 04:24 2008-09-22 Trinad Capital Master Fund Ltd. 10% owner BUY $0.22 269,500 $59,290 6,741,127 +4.2%
2008-09-22 19:57 2008-09-18 Berg Jeffrey Alan Director BUY $0.25 1,544,145 $384,647 4,219,600 +57.7%
2008-09-19 04:21 2008-07-28 Trinad Capital Master Fund Ltd. 10% owner BUY $0.23 641,800 $148,962 6,471,627 +11.0%
2008-09-18 00:49 2008-09-16 Farricielli Joseph J. Jr. Director BUY $0.21 10,000 $2,100 16,000 +166.7%
2008-09-13 02:09 2008-09-10 Farricielli Joseph J. Jr. Director BUY $0.25 6,000 $1,520 6,000 +100.0%
2007-09-06 04:01 2007-08-31 Bourbiel Jennifer Officer - Vice President, Marketing BUY $0.94 15,000 $14,100 15,000 +100.0%
2007-08-17 01:30 2007-08-15 CLASEN ROBERT B Director BUY $0.90 10,000 $9,031 50,000 +25.0%
2006-09-01 21:53 2006-08-31 Berger Kendra Officer - Chief Financial Officer BUY $1.28 20,000 $25,600 20,000 +100.0%
2006-08-30 00:54 2006-08-25 Santana Dario Loreto Director, Officer - President and CEO BUY $1.19 50,000 $59,520 50,000 +100.0%
2006-08-22 00:12 2006-08-18 CLASEN ROBERT B Director BUY $1.18 10,000 $11,800 40,000 +33.3%
2006-05-19 02:12 2006-05-16 CLASEN ROBERT B Director BUY $1.61 10,000 $16,100 30,000 +50.0%
SHOW ENTRIES

How to Interpret $NTN Trades

Not every insider transaction in Ernexa Therapeutics Inc. is a signal for immediate action. Professional investors look for "cluster buying"—when multiple executives simultaneously purchase $NTN shares on the open market. It is crucial to distinguish between scheduled sales (under Rule 10b5-1) and voluntary increases in ownership, which demonstrate management’s true conviction that the stock is undervalued.

Data Source & Accuracy for NTN

Insider activity data for Ernexa Therapeutics Inc. is streamed in real-time directly from the SEC EDGAR system. We analyze raw Form 4 filings, filtering out technical adjustments and complex derivative transactions. This provides a transparent view of how ownership structure is evolving in $NTN, allowing you to follow the capital of those with the most intimate knowledge of the company.

UNDERSTANDING THE DATA

FILING DATE: The date and time when the transaction was reported to the SEC. This is when the public first receives the information.

TRADE DATE: The actual day the insider executed the purchase or sale in the market.

INDUSTRY: The specific market sector the company operates in. Useful for identifying broader institutional capital flows across sectors.

OWNED AFTER: The total number of shares held by the insider following the transaction. This highlights the insider's remaining conviction in the company.

CHANGE %: The percentage increase or decrease of the insider's total position. Large percentage changes often carry more weight than the dollar amount alone.

TRADE TYPES DEFINITIONS

BUY: An open market purchase. Typically indicates an insider's belief that the stock is undervalued or poised for growth.

SELL: An open market sale. While often used for diversification or liquidity, large or unexpected sales can be a warning signal.

OPT+S (OPTION EXERCISE & SALE): This occurs when an insider exercises their stock options and sells them immediately. Often part of a structured compensation plan.